Kevin Pang, PharmD

The adjuvant therapy has demonstrated varied efficacy for patients.

This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.

Systemic treatment options have historically been limited to traditional chemotherapy agents.

Significant advancements have changed the treatment landscape and clinical practice procedures.

Specific immune checkpoint inhibitors added to frontline chemotherapy have transformed modern clinical practice.